Molekulare Grundlagen der Apoptose

  • Peter Daniel
Chapter

Auszug

Mit der Evolution multizellulärer Organismen wurde es nötig, genetische Programme zu entwickeln, die soziale Interaktionen im Gewebsverband regulieren. Die Entwicklung spezialisierter Gewebe erfordert nicht nur Zellwachstum an der richtigen Stelle und Differenzierung in die entsprechenden spezialisierten Zelltypen, sondern auch die gezielte Elimination überflüssiger oder gar unerwünschter Zellen. Um diesen „altruistischen“ Zelltod zu regulieren, haben tierische Zellen genetisch determinierte Regulationsmechanismen entwickelt, die im entwicklungsbiologischen Kontext als „programmierter Zelltod“ bezeichnet werden, da der Zelltod durch genetisch determinierte Programme zu genau definierten Zeitpunkten in den zu eliminierenden Gewebsarealen induziert wird. Dieser Begriff umfasst verschiedene Zelltodtypen, von denen die Apoptose der am besten untersuchte Mechanismus ist (Golstein et al. 2003).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O’Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P and Cory S (2005). Subversion of the Bcl-2 life/death switch in cancer development and therapy. Cold Spring Harb Symp Quant Biol 70:469–477PubMedGoogle Scholar
  2. Ahr B, Robert-Hebmann V, Devaux C and Biard-Piechaczyk M (2004). Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 1:12PubMedGoogle Scholar
  3. Ameisen JC (1998). HIV. Setting death in motion. Nature 395: 117,119PubMedGoogle Scholar
  4. Anderson MK (2006). At the crossroads: diverse roles of early thymocyte transcriptional regulators. Immunol Rev 209:191–211PubMedGoogle Scholar
  5. Baell JB and Huang DC (2002). Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 64:851–863PubMedGoogle Scholar
  6. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G and Peter ME (2004). CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. Embo J 23: 3175–3385PubMedGoogle Scholar
  7. Baylin SB and Ohm JE (2006). Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:17–16Google Scholar
  8. Bentzen SM (2006). Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6: 702–713PubMedGoogle Scholar
  9. Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M and Hanski C (2006). Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 25: 165–175PubMedGoogle Scholar
  10. Bidere N, Su HC and Lenardo MJ (2006). Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 24:321–352PubMedGoogle Scholar
  11. Breckenridge DG, Nguyen M, Kuppig S, Reth M and Shore GC (2002). The procaspase-8 isoform, procaspase-8L, recruited to the BAP31 complex at the endoplasmic reticulum. Proc Natl Acad Sci USA 99:4331–4336PubMedGoogle Scholar
  12. Bredesen DE, Rao RVand Mehlen P (2006). Cell death in the nervous system. Nature 443: 796–802PubMedGoogle Scholar
  13. Brewer JWand Diehl JA (2000). PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci USA 97:12625–12630PubMedGoogle Scholar
  14. Brown JM and Attardi LD (2005). The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231–237PubMedGoogle Scholar
  15. Brown JM and Wilson G (2003). Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2:477–490PubMedGoogle Scholar
  16. Budd RC, Yeh WC and Tschopp J (2006). cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 6: 196–204PubMedGoogle Scholar
  17. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F and Croce CM (2002). Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524–15529PubMedGoogle Scholar
  18. Cam H and Dynlacht BD (2003). Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3: 311–316PubMedGoogle Scholar
  19. Chabner BA and Roberts TG, Jr. (2005). Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72PubMedGoogle Scholar
  20. Chandra D, Choy G, Daniel PT and Tang DG (2005). Bax-dependent regulation of Bak by voltage-dependent anion channel 2. J Biol Chem 280:19051–19061PubMedGoogle Scholar
  21. Chandrashekhar Y, Sen S, Anway R, Shuros A and Anand I (2004). Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-l cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 43: 295–301PubMedGoogle Scholar
  22. Chen L, Willis SN, Wei A, Smith BJ, Fletcher Jl, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393–403PubMedGoogle Scholar
  23. Chisari FV(1996). Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 206:149–173Google Scholar
  24. Choo AY and Blenis J (2006). TORgeting oncogene addiction for cancer therapy. Cancer Cell 9: 77–79PubMedGoogle Scholar
  25. Cimmino A, Calin GA, Fabbri M, lorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M and Croce CM (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949PubMedGoogle Scholar
  26. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, Craessaerts K, Metzger K, Frezza C, Annaert W, D’Adamio L, Derks C, Dejaegere T, Pellegrini L, D’Hooge R, Scorrano L and De Strooper B (2006). Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126:163–175PubMedGoogle Scholar
  27. Clarke PG (1990). Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol (Berl) 181:195–213Google Scholar
  28. Clarke PG and Clarke S (1996). Nineteenth century research on naturally occurring cell death and related phenomena. Anat Embryol (Berl) 193:81–99Google Scholar
  29. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM and Lindquist S (2006). Alpha-synuclein blocks ER-Golgi traffic and Rabi rescues neuron loss in Parkinson’s models. Science 313: 324–328PubMedGoogle Scholar
  30. Cory S, Vaux DL, Strasser A, Harris AW and Adams JM (1999). Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 59: 1685s–1692s.PubMedGoogle Scholar
  31. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP and Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194–198PubMedGoogle Scholar
  32. Daniel PT (2003). Zellzyklus und Apoptose. Molekulare Grundlagen von hämatologischen Neoplasien. Springer-Verlag Berlin Heidelberg 11:130–184Google Scholar
  33. Daniel PT, Schulze-Osthoff K, Belka C and Güner D (2003). Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 39: 73–88PubMedGoogle Scholar
  34. Daniel PT, Sturm I, Hemmati PG and Güner D (2004). Pharmakogenomik maligner Tumoren — Bedeutung von Zellzyklus-und Apoptosedefekten für Therapieansprechen und Krankheitsprognose. Onkologe 10:46–54Google Scholar
  35. Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K (2001). The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022–1032PubMedGoogle Scholar
  36. de Lange T (2002). Protection of mammalian telomeres. Oncogene 21:532–540PubMedGoogle Scholar
  37. Defrance T (2005). Mature B cells: apoptosis checkpoints. Transplantation 79: S4–7PubMedGoogle Scholar
  38. Dhein J, Walczak H, Baumler C, Debatin KM and Krammer PH (1995). AutocrineT-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438–441PubMedGoogle Scholar
  39. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H and Marynen P (1999). The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosaassociated lymphoid tissue lymphomas. Blood 93: 3601–3609PubMedGoogle Scholar
  40. Dimri GP (2005). What has senescence got to do with cancer? Cancer Cell 7:505–512PubMedGoogle Scholar
  41. Duplain H (2006). Salvage of ischemic myocardium: a focus on JNK. Adv Exp Med Biol 588:157–164PubMedGoogle Scholar
  42. Dutta J, Fan Y, Gupta N, Fan G and Gelinas C (2006). Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800–6816PubMedGoogle Scholar
  43. Easton JB and Houghton PJ (2006). mTOR and cancer therapy. Oncogene 25:6436–6446PubMedGoogle Scholar
  44. Egle A, Harris AW, Bouillet P and Cory S (2004). Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101:6164–6169PubMedGoogle Scholar
  45. Eischen CM, Roussel MF, Korsmeyer SJ and Cleveland JL (2001). Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21: 7653–7662PubMedGoogle Scholar
  46. Eischen CM, Weber JD, Roussel MF, Sherr CJ and Cleveland JL (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658–2669PubMedGoogle Scholar
  47. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391:43–50PubMedGoogle Scholar
  48. Essmann F, Bantel H, Totzke G, Engels IH, Sinha B, Schulze-Osthoff K and Janicke RU (2003). Staphylococcus aureus alpha-toxin-induced cell death: predominant necrosis despite apoptotic caspase activation. Cell Death Differ 10:1260–1272PubMedGoogle Scholar
  49. Fanidi A, Harrington EA and Evan Gl (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554–556PubMedGoogle Scholar
  50. Fas SC, Fritzsching B, Suri-Payer E and Krammer PH (2006). Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 9:1–17PubMedGoogle Scholar
  51. Fesik SW (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885PubMedGoogle Scholar
  52. Fischer U, Stroh C and Schulze-Osthoff K (2006). Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene 25:152–159PubMedGoogle Scholar
  53. Fletcher JI and Huang DC (2006). BH3-only proteins: orchestrating cell death. Cell Death Differ 13:1268–1271PubMedGoogle Scholar
  54. Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE and Mehlen P (2001). The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A 98:3416–3421PubMedGoogle Scholar
  55. Friedlander RM (2003). Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348:1365–1375PubMedGoogle Scholar
  56. Frisch SM and Francis H (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626PubMedGoogle Scholar
  57. Fulda S, Wick W, Weiler M and Debatin KM (2002). Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808–815PubMedGoogle Scholar
  58. Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, Thivolet F, Etienne J, Lina G, Vallette FM, Vandenesch F and Genestier L (2005). Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Baxindependent apoptosis of human neutrophils. J Clin Invest 115:3117–3127PubMedGoogle Scholar
  59. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dörken B, Schulze-Osthoff K and Daniel PT (2003). Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. Embo J 22: 3580–3590PubMedGoogle Scholar
  60. Gilmore AP (2005). Anoikis. Cell Death Differ 12Suppl 2:1473–1477PubMedGoogle Scholar
  61. Goedert M and Spillantini MG (2006). A century of Alzheimer’s disease. Science 314: 777–781PubMedGoogle Scholar
  62. Golstein P, Aubry L and Levraud JP (2003). Cell-death alternative model organisms: why and which? Nat Rev Mol Cell Biol 4: 798–807PubMedGoogle Scholar
  63. Groux H, Torpier G, Monte D, Mouton Y, Capron A and Ameisen JC (1992). Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 175:331–340PubMedGoogle Scholar
  64. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM and Ron D (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11:619–633PubMedGoogle Scholar
  65. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K and Singleton A (2006). Genetics of Parkinson’s disease and parkinsonism. Ann Neural 60:389–398Google Scholar
  66. Hasenjager A, Gillissen B, Muller A, Normand G, Hemmati PG, Schuler M, Dörken B and Daniel PT (2004). Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene 23:4523–4535PubMedGoogle Scholar
  67. Hemmati PG, Guner D, Gillissen B, Wendt J, von Haefen C, Chinnadurai G, Dörken B and Daniel PT (2006). Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene 25:6582–6594PubMedGoogle Scholar
  68. Hilfiker-Kleiner D, Landmesser U and Drexler H (2006). Molecular mechanisms in heart failure focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 48: A56–66Google Scholar
  69. Hingorani SR and Tuveson DA (2003). Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev 13:6–13PubMedGoogle Scholar
  70. Hockemeyer D, Sfeir AJ, Shay JW, Wright WE and de Lange T (2005). POT 1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. Embo J 24:2667–2678PubMedGoogle Scholar
  71. Hotchkiss RS and Nicholson DW (2006). Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6: 813–822PubMedGoogle Scholar
  72. Jonkers J and Berns A (2004). Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6: 535–538PubMedGoogle Scholar
  73. Kang TB, Ben-Moshe T, Varfolomeev EE, Pewzner-Jung Y, Yogev N, Jurewicz A, Waisman A, Brenner O, Haffner R, Gustafsson E, Ramakrishnan P, Lapidot T and Wallach D (2004). Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol 173: 2976–2984PubMedGoogle Scholar
  74. Kastan MB and Bartek J (2004). Cell-cycle checkpoints and cancer. Nature432: 316–323PubMedGoogle Scholar
  75. Kerr JF, Wyllie AH and Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257PubMedGoogle Scholar
  76. Kim HE, Du F, Fang M and Wang X (2005). Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci USA 102:17545–17550PubMedGoogle Scholar
  77. Kim R, Emi M, Tanabe K and Murakami S (2006). Role of the unfolded protein response in cell death. Apoptosis 11:5–13PubMedGoogle Scholar
  78. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 14: 5579–5588PubMedGoogle Scholar
  79. Knudson CM, Tung KS, Tourtellotte WG, Brown GA and Korsmeyer SJ (1995). Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96–99PubMedGoogle Scholar
  80. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH (1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415–1420PubMedGoogle Scholar
  81. Krammer PH (2000). CD95’s deadly mission in the immune system. Nature 407: 789–795PubMedGoogle Scholar
  82. Krysko DV, D’Herde K and Vandenabeele P (2006). Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11:1709–1726PubMedGoogle Scholar
  83. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR and Newmeyer DD (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17:525–535PubMedGoogle Scholar
  84. Lam E (2004). Controlled cell death, plant survival and development. Nat Rev Mol Cell Biol 5: 305–315PubMedGoogle Scholar
  85. Lara-Tejero M, Sutterwala FS, Ogura Y, Grant EP, Bertin J, Coyle AJ, Flavell RA and Galan JE (2006). Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med 203:1407–1412PubMedGoogle Scholar
  86. Lavin MF, Delia D and Chessa L (2006). ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes. EMBO Rep 7:154–160PubMedGoogle Scholar
  87. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F and Gambacorti-Passerini C (1999). In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163–168PubMedGoogle Scholar
  88. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S and Korsmeyer SJ (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183–192PubMedGoogle Scholar
  89. Lettre G and Hengartner MO (2006). Developmental apoptosis in C. elegans: a complex CEDnario. Nat Rev Mol Cell Biol 7: 97–108PubMedGoogle Scholar
  90. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489PubMedGoogle Scholar
  91. Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, Herceg Z, Wang ZQ and Schulze-Osthoff K (2002). Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell 13:978–988PubMedGoogle Scholar
  92. Ludewig B, Gelderblom HR, Becker Y, Schafer A and Pauli G (1996). Transmission of HIV-1 from productively infected mature Langerhans cells to primary CD4+ T lymphocytes results in altered T cell responses with enhanced production of IFN-gamma and IL-10. Virology 215: 51–60PubMedGoogle Scholar
  93. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T and Thompson CB (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120: 237–248PubMedGoogle Scholar
  94. Marciniak SJ and Ron D (2006). Endoplasmic reticulum stress signaling in disease. Physiol Rev 86:1133–1149PubMedGoogle Scholar
  95. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W and Belka C (2006). Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25:5145–5154PubMedGoogle Scholar
  96. Martinou JC and Green DR (2001). Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67PubMedGoogle Scholar
  97. May P and May E (1999). Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621–7636PubMedGoogle Scholar
  98. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP and Korsmeyer SJ (1989). bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79–88PubMedGoogle Scholar
  99. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Embo J 16: 2794–2804PubMedGoogle Scholar
  100. Mehlen P (2005). The dependence receptor notion: another way to see death. Cell Death Differ 12:1003PubMedGoogle Scholar
  101. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS and Bredesen DE (1998). The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395: 801–804PubMedGoogle Scholar
  102. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C and Grutter MG (2002). The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277:45162–45171PubMedGoogle Scholar
  103. Micheau O and Tschopp J (2003). Induction of TNF receptor l-mediated apoptosis via two sequential signaling complexes. Cell 114:181–190PubMedGoogle Scholar
  104. Molz L, Booher R, Young P and Beach D (1989). cdc2 and the regulation of mitosis: six interacting mcs genes. Genetics 122: 773–782PubMedGoogle Scholar
  105. Muller A, Gunther D, Brinkmann V, Hurwitz R, Meyer TF and Rudel T (2000). Targeting of the pro-apoptotic VDAC-like porin (PorB) of Neisseria gonorrhoeae to mitochondria of infected cells. Embo J 19:5332–5343PubMedGoogle Scholar
  106. Murray-Zmijewski F, Lane DP and Bourdon JC (2006). p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13:962–972PubMedGoogle Scholar
  107. Newell MK, Haughn LJ, Maroun CR and Julius MH (1990). Death of matureTcells by separate ligation of CD4 and theT-cell receptor for antigen. Nature 347:286–289PubMedGoogle Scholar
  108. Normand G, Hemmati PG, Verdoodt B, von Haefen C, Wendt J, Guner D, May E, Dörken B and Daniel PT(2005). p14ARF induces G2 cell cycle arrest in p53-and p21-deficient cells by down-regulating p34cdc2 kinase activity. J Biol Chem 280: 7118–7130PubMedGoogle Scholar
  109. Ogura Y, Sutterwala FS and Flavell RA (2006). The inflammasome: first line of the immune response to cell stress. Cell 126: 659–662PubMedGoogle Scholar
  110. Okada H and Mak TW (2004). Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4:592–603PubMedGoogle Scholar
  111. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW and Rosenberg SH (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681PubMedGoogle Scholar
  112. Orren DK (2006). Werner syndrome: molecular insights into the relationships between defective DNA metabolism, genomic instability, cancer and aging. Front Biosci 11: 2657–2671PubMedGoogle Scholar
  113. Palmer E (2003). Negative selection clearing out the bad apples from theT-cell repertoire. Nat Rev Immunol 3:383–391PubMedGoogle Scholar
  114. Pardo J, Urban C, Galvez EM, Ekert PG, Muller U, Kwon-Chung J, Lobigs M, Mullbacher A, Wallich R, Borner C and Simon MM (2006). The mitochondrial protein Bak is pivotal for gliotoxininducedapoptosis and a critical host factor of Aspergillus fumigatus virulence in mice. J Cell Biol 174: 509–519PubMedGoogle Scholar
  115. Pei XH and Xiong Y (2005). Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24:2787–2795PubMedGoogle Scholar
  116. Priault M, Bessoule JJ, Grelaud-Coq A, Camougrand N and Manon S (2002). Bax-induced cell death in yeast depends on mitochondrial lipid oxidation. Eur J Biochem 269: 5440–5450PubMedGoogle Scholar
  117. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B and Daniel PT (2003). Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391–3401PubMedGoogle Scholar
  118. Riedl SJ and Shi Y (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5:897–907PubMedGoogle Scholar
  119. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C and DePinho RA (1999). Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96:701–712PubMedGoogle Scholar
  120. Sansal I and Sellers WR (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954–2963PubMedGoogle Scholar
  121. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT (2005). Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24:1904–1913PubMedGoogle Scholar
  122. Schweichel JU and Merker HJ (1973). The morphology of various types of cell death in prenatal tissues. Teratology 7:253–266Google Scholar
  123. Schwerk C and Schulze-Osthoff K (2003). Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 66:1453–1458PubMedGoogle Scholar
  124. Scott AM and Saleh M (2007). The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ 14: 23–31PubMedGoogle Scholar
  125. Searle J, Lawson TA, Abbott PJ, Harmon B and Kerr JF (1975). An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 116:129–138PubMedGoogle Scholar
  126. Sengupta S and Harris CC (2005). p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6: 44–55PubMedGoogle Scholar
  127. Shao Z, Bhattacharya K, Hsich E, Park L, Walters B, Germann U, Wang YM, Kyriakis J, Mohanlal R, Kuida K, Namchuk M, Salituro F, Yao YM, Hou WM, Chen X, Aronovitz M, Tsichlis PN, Bhattacharya S, Force T and Kilter H (2006). c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res 98:111–118PubMedGoogle Scholar
  128. Shen J and Prywes R (2004). Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6. J Biol Chem 279: 43046–43051PubMedGoogle Scholar
  129. Sherr CJ (1998). Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984–2991PubMedGoogle Scholar
  130. Sherr CJ (2006). Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6:663–673PubMedGoogle Scholar
  131. Shi Y (2004). Caspase activation: revisiting the induced proximity model. Cell 117:855–858PubMedGoogle Scholar
  132. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y (2004). Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6:1221–1228PubMedGoogle Scholar
  133. Strasser A (2005). The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189–200PubMedGoogle Scholar
  134. Strasser A, Harris AW, Bath ML and Cory S (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–333PubMedGoogle Scholar
  135. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT and Bargou RC (2005). Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106:3609–3617PubMedGoogle Scholar
  136. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B and Daniel PT (2001). Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 19: 2272–2281PubMedGoogle Scholar
  137. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S, Jung K, Loening S, Dörken B and Daniel PT (2006). Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 13: 619–627PubMedGoogle Scholar
  138. Szegezdi E, Logue SE, Gorman AM and Samali A (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7:880–885PubMedGoogle Scholar
  139. Tinel A, Janssens S, Lippens S, Cuenin S, Logette E, Jaccard B, Quadroni M and Tschopp J (2007). Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and prosurvival NF-kappaB pathway. Embo J 26:197–208PubMedGoogle Scholar
  140. Toledo F and Wahl GM (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923PubMedGoogle Scholar
  141. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H and Wajant H (2006). TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25:7434–7439PubMedGoogle Scholar
  142. Tsujimoto Y and Croce CM (1986). Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214–5218PubMedGoogle Scholar
  143. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097–1099PubMedGoogle Scholar
  144. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW and Huang DC (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/ Bax if Mcl-1 is neutralized. Cancer Cell 10:389–399PubMedGoogle Scholar
  145. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848PubMedGoogle Scholar
  146. Vaux DL, Cory S and Adams JM (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442PubMedGoogle Scholar
  147. Verdun RE and Karlseder J (2006). The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell 127: 709–720PubMedGoogle Scholar
  148. von Boehmer H and Fehling HJ (1997). Structure and function of the pre-T cell receptor. Annu Rev Immunol 15:433–452Google Scholar
  149. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Güner D, Mrozek A, Belka C, Dörken B and Daniel PT (2004). Multidomain Bcl-2 homolog Bax but not Bakmediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23:8320–8332Google Scholar
  150. Voskoboinik I, Smyth MJ and Trapani JA (2006). Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6:940–952PubMedGoogle Scholar
  151. Vousden KH and Lu X (2002). Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604PubMedGoogle Scholar
  152. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C and Reed JC (2004). Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 279:48168–48176PubMedGoogle Scholar
  153. Wendt J, Radetzki S, von Haefen C, Hemmati PG, Guner D, Schulze-Osthoff K, Dörken B and Daniel PT(2006). Induction of p21 CIP/ WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene 25: 972–980PubMedGoogle Scholar
  154. Wendt J, von Haefen C, Hemmati P, Belka C, Dörken B and Daniel PT (2005). TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24:4052–4064PubMedGoogle Scholar
  155. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM and Krammer PH (1995). Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp 120. Nature 375:497–500PubMedGoogle Scholar
  156. White E (2006). Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ 13: 1371–1377PubMedGoogle Scholar
  157. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294–1305PubMedGoogle Scholar
  158. Wyllie AH (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555–556PubMedGoogle Scholar
  159. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ and Firestein GS (2002). Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 99: 10025–10030PubMedGoogle Scholar
  160. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng 71, Jones DP and Wang X (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129–1132PubMedGoogle Scholar
  161. Yoo CB and Jones PA (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37–50PubMedGoogle Scholar
  162. Youle RJ and Karbowski M (2005). Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol 6:657–663PubMedGoogle Scholar
  163. Yuan J, Shaham S, Ledoux S, Ellis HM and Horvitz HR (1993). The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75: 641–652PubMedGoogle Scholar
  164. Zhang F, Hamanaka RB, Bobrovnikova-Marjon E, Gordan JD, Dai MS, Lu H, Simon MC and Diehl JA (2006a). Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest. J Biol Chem 281:30036–30045PubMedGoogle Scholar
  165. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, Macdonald ME, Hayden MR and Friedlander RM (2006b). Huntingtin inhibits caspase-3 activation. Embo J 25:5896–5906PubMedGoogle Scholar
  166. Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR and Friedlander RM (2003a). Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 87:101–116PubMedGoogle Scholar
  167. Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, Ferrante RJ and Friedlander RM (2003b). Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington’s disease. J Neurochem 87:1184–1192PubMedGoogle Scholar
  168. Zhivotovsky B and Orrenius S (2005). Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331: 859–867PubMedGoogle Scholar
  169. Zong WX, Ditsworth D, Bauer DE, Wang ZQ and Thompson CB (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18:1272–1282PubMedGoogle Scholar

Literatur zur Zeittafel

  1. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH and Wallach D (1995). A novel protein that interacts with the death domain of Fas/APOl contains a sequence motif related to the death domain. J Biol Chem 270: 7795–7798PubMedGoogle Scholar
  2. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM and Strasser A (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735–1738PubMedGoogle Scholar
  3. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393–403PubMedGoogle Scholar
  4. Chinnaiyan AM, O’Rourke K, Tewari M and Dixit VM (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505–512PubMedGoogle Scholar
  5. Clarke PG and Clarke S (1996). Nineteenth century research on naturally occurring cell death and related phenomena. Anat Embryol (Berl) 193:81–99Google Scholar
  6. Collin R (1906). Recherches cytologiques sur le développement de la cellule nerveuse. Névraxe 8:181–309Google Scholar
  7. Crook NE, Clem RJ and Miller LK (1993). An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 67: 2168–2174PubMedGoogle Scholar
  8. Daniel PT and Krammer PH (1994). Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 152:5624–5632PubMedGoogle Scholar
  9. De Bruyne C (1898). Recherches au sujet de l’intervention de la phagocytose dans le développement des invertébrés. Arch Biol 15:181–300Google Scholar
  10. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou JC (1999). Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedGoogle Scholar
  11. Dhein J, Walczak H, Bäumler C, Debatin KM and Krammer PH (1995). AutocrineT-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438–441PubMedGoogle Scholar
  12. Du C, Fang M, Li Y, Li L and Wang X (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33–42PubMedGoogle Scholar
  13. Ellis HM and Horvitz HR (1986). Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817–829PubMedGoogle Scholar
  14. Eskes R, Desagher S, Antonsson B and Martinou JC (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20:929–935PubMedGoogle Scholar
  15. Fanidi A, Harrington EA and Evan GI (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554–556PubMedGoogle Scholar
  16. Felix W (1889). Ueber Wachsthum der quergestreiften Muskulatur nach Beobachtungen am Menschen. Z Wiss Zool 48:224–259Google Scholar
  17. Flemming W (1885). Ueber die Bildung von Richtungsfiguren in Säugethiereiern beim Untergang Graaf’cher Follikel. Anat Physiol Jahrgang 1885: 221–244Google Scholar
  18. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dörken B, Schulze-Osthoff Kand Daniel PT(2003). Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. Embo J 22: 3580–3590PubMedGoogle Scholar
  19. Glücksmann A (1951). Cell deaths in normal vertebrate ontogeny. Biol Rev Camb Philes Soc 26: 59–86Google Scholar
  20. Gräper L (1914). Eine neue Anschauung über physiologische Zellausschaltung. Arch Zellforsch 12: 373–394Google Scholar
  21. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC and Raff MC (1993). Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365–369PubMedGoogle Scholar
  22. Kerr JF, Wyllie AH and Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257PubMedGoogle Scholar
  23. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 14: 5579–5588PubMedGoogle Scholar
  24. Lam M, Dubyak G, Chen L, Nunez G, Miesfeld RL and Distelhorst CW (1994). Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA 91:6569–6573PubMedGoogle Scholar
  25. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F and Gambacorti-Passerini C (1999). In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163–168PubMedGoogle Scholar
  26. Li P, Nijhawan D, Budihardjol, Srinivasula SM, Ahmad M, Alnemri ES and Wang X(1997). Cytochromec and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489PubMedGoogle Scholar
  27. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B (1999). Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402:672–676PubMedGoogle Scholar
  28. Liu X, Kim CN, Yang J, Jemmerson R and Wang X (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147–157PubMedGoogle Scholar
  29. Lundblad Vand Szostak JW (1989). A mutant with a defect in telomere elongation leads to senescence in yeast. Cell 57: 633–643Google Scholar
  30. Marx J (2002). Nobel Prize in Physiology or Medicine. Tiny worm takes a star turn. Science 298: 526PubMedGoogle Scholar
  31. Mayer S (1886). Die sogenannten Sarkoplasten. Anat Anz 1: 231–235Google Scholar
  32. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP and Korsmeyer SJ (1989). bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57: 79–88PubMedGoogle Scholar
  33. Mehlen P and Bredesen DE (2000). Dependence receptors: links between apoptosis, nervous system development and control of tumorigenesis. Bull Cancer 87: 537–541PubMedGoogle Scholar
  34. Metchnikoff E (1892). La phagocytose musculaire. I. Atrophie des muscles pendant la transformation des batraciens. Ann Inst Pasteur 6:1–12Google Scholar
  35. Metschnikof E (1883). Untersuchungen über die mesodermalen Phagocyten einiger Wirbeltiere. Biol Zentralbl 3: 560–565Google Scholar
  36. Molz L, Booher R, Young P and Beach D (1989). cdc2 and the regulation of mitosis: six interacting mes genes. Genetics 122: 773–782PubMedGoogle Scholar
  37. Muzio M, Chinnaiyan AM, Kischkel FC, O’Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death-inducing signaling complex. Cell 85:817–827PubMedGoogle Scholar
  38. Nakano K and Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683–694PubMedGoogle Scholar
  39. O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S and Huang DC(1998). Bim:a novel member of the Bcl-2 family that promotes apoptosis. Embo J 17: 384–395PubMedGoogle Scholar
  40. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petras AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW and Rosenberg SH (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681PubMedGoogle Scholar
  41. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619PubMedGoogle Scholar
  42. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277:815–818PubMedGoogle Scholar
  43. Pelengaris S, Littlewood T, Khan M, Elia G and Evan G (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565–577PubMedGoogle Scholar
  44. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB and Fesik SW (1997). Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983–986PubMedGoogle Scholar
  45. Schweichel JU and Merker HJ (1973). The morphology of various types of cell death in prenatal tissues. Teratology 7:253–266Google Scholar
  46. Searle J, Lawson TA, Abbott PJ, Harmon B and Kerr JF (1975). An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 116:129–138PubMedGoogle Scholar
  47. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821PubMedGoogle Scholar
  48. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y (2004). Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6:1221–1228PubMedGoogle Scholar
  49. Stieda L (1872). Die Bildung des Knochengewebes. Festschrift des Naturforschervereins zu Riga zur Feier des fünfzigjährigen Bestehens der Gesellschaft practischer ärtzezu Riga. Engelmann, LeipzigGoogle Scholar
  50. Strasser A, Harris AW, Bath ML and Cory S (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–333PubMedGoogle Scholar
  51. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S and Harris AW (1991). Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88:8661–8665PubMedGoogle Scholar
  52. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S, Jung K, Loening S, Dörken B and Daniel PT (2006). Loss of the tissuespecific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 13:619–627PubMedGoogle Scholar
  53. Suda T and Nagata S (1994). Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179:873–879PubMedGoogle Scholar
  54. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM and Krammer PH (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301–305PubMedGoogle Scholar
  55. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097–1099PubMedGoogle Scholar
  56. Uren AG, Pakusch M, Hawkins CJ, Puls KL and Vaux DL (1996). Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 93: 4974–4978PubMedGoogle Scholar
  57. Vaux DL, Cory S and Adams JM (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442PubMedGoogle Scholar
  58. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43–53PubMedGoogle Scholar
  59. Virchow R (1871) Vorlesungen über Pathologie: Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. 4. Auflage, Verlag von August Hirschwald, BerlinGoogle Scholar
  60. Vogt C (1842). Untersuchungen über die Entwicklungsgeschichte der Geburtshelferkröte (Alytes obstetricans). Jent und Gassmann, SolothurnGoogle Scholar
  61. Weinstein IB (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297:63–64PubMedGoogle Scholar
  62. Weissmann A (1863). Die Entwickelung der Dipteren im Ei nach Beobachtungen an Chironomus spec, Musca vomitoria und Pulex canis. Z Wiss Zool 13:107–220Google Scholar
  63. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682PubMedGoogle Scholar
  64. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294–1305PubMedGoogle Scholar
  65. Wyllie AH (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555–556PubMedGoogle Scholar
  66. Yang E, Zha J, Jockei J, Boise LH, Thompson CB and Korsmeyer SJ (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285–291PubMedGoogle Scholar
  67. Yonehara S, Ishii A and Yonehara M (1989). A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747–1756PubMedGoogle Scholar
  68. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345–347PubMedGoogle Scholar
  69. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T and Simon HU (2006). Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 8: 1124–1132PubMedGoogle Scholar
  70. Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L (2003). PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100:1931–1936PubMedGoogle Scholar
  71. Yu J, Zhang L, Hwang PM, Kinzler KW and Vogelstein B (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673–682PubMedGoogle Scholar
  72. Yuan J, Shaham S, Ledoux S, Ellis HM and Horvitz HR (1993). The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75: 641–652PubMedGoogle Scholar
  73. Zou H, Henzel WJ, Liu X, Lutschg A and Wang X (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405–413PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Peter Daniel
    • 1
  1. 1.Klinische und Molekulare OnkologieCharité - Universitätsmedizin BerlinBerlin

Personalised recommendations